Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone intervention for non-alcoholic fatty liver disease and metabolic disorders in adults with pituitary stalk interruption syndrome
ChiCTR2600135816Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of somatropin in Pituitary stalk interruption syndrome (PSIS), metabolic dysfunction-associated steatotic liver disease (MASLD), growth hormone deficiency (GHD) and 1 more (5 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Fatty liver. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
somatropin
03
Conditions
Pituitary stalk interruption syndrome (PSIS)metabolic dysfunction-associated steatotic liver disease (MASLD)growth hormone deficiency (GHD)hypopituitarism
Beyond the preview
Go deeper on ChiCTR2600135816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135816.